These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30930066)

  • 21. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
    Pittet CL; Newcombe J; Prat A; Arbour N
    J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Miniprotein engineering for inhibition of PD-1/PD-L1 interaction.
    Ciesiołkiewicz A; Lizandra Perez J; Skalniak L; Noceń P; Berlicki Ł
    Protein Sci; 2024 Aug; 33(8):e5106. PubMed ID: 39012010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.
    Bastaki S; Irandoust M; Ahmadi A; Hojjat-Farsangi M; Ambrose P; Hallaj S; Edalati M; Ghalamfarsa G; Azizi G; Yousefi M; Chalajour H; Jadidi-Niaragh F
    Life Sci; 2020 Apr; 247():117437. PubMed ID: 32070710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Probing protein flexibility reveals a mechanism for selective promiscuity.
    Pabon NA; Camacho CJ
    Elife; 2017 Apr; 6():. PubMed ID: 28432789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery.
    Tang S; Kim PS
    Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24500-24506. PubMed ID: 31727844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural Insights of PD-1/PD-L1 Axis: An
    Rohit S; Patel M; Jagtap Y; Shah U; Patel A; Patel S; Solanki N
    Curr Protein Pept Sci; 2024; 25(8):638-650. PubMed ID: 38706351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
    Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
    [No Abstract]   [Full Text] [Related]  

  • 30. Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
    Zhou K; Lu J; Yin X; Xu H; Li L; Ma B
    Biophys Chem; 2019 Oct; 253():106213. PubMed ID: 31276987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational design of a synthetic PD-1 agonist.
    Bryan CM; Rocklin GJ; Bick MJ; Ford A; Majri-Morrison S; Kroll AV; Miller CJ; Carter L; Goreshnik I; Kang A; DiMaio F; Tarbell KV; Baker D
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34272285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.
    Ishida M; Iwai Y; Tanaka Y; Okazaki T; Freeman GJ; Minato N; Honjo T
    Immunol Lett; 2002 Oct; 84(1):57-62. PubMed ID: 12161284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
    Fujiwara K; Shigematsu K; Tachibana M; Okada N
    IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
    Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
    Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).
    Kamalinia G; Engel BJ; Srinivasamani A; Grindel BJ; Ong JN; Curran MA; Takahashi TT; Millward SW; Roberts RW
    ACS Chem Biol; 2020 Jun; 15(6):1630-1641. PubMed ID: 32352272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
    Liu J; Li H; Sun L; Yuan Y; Xing C
    Biomed Res Int; 2020; 2020():2496582. PubMed ID: 32596285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
    Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
    Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction.
    Kawashita S; Aoyagi K; Yamanaka H; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Fukushima K; Miyazaki S; Hantani Y
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2464-2467. PubMed ID: 31351692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infection.
    Zhang E; Zhang X; Liu J; Wang B; Tian Y; Kosinska AD; Ma Z; Xu Y; Dittmer U; Roggendorf M; Yang D; Lu M
    PLoS One; 2011; 6(10):e26196. PubMed ID: 22022563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.